An update on the efficacy and safety of iloperidone as a schizophrenia therapy

References

• Simeone JC, Ward AJ, Rotella P, et al. An evaluation of variation in published estimates of schizophrenia prevalence from 1990 horizontal line 2013: a systematic literature review. BMC Psychiatry. 2015;15:193.
   PubMed Web of Science ®Google Scholar
• Kurtz M. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res. 2005;74:15–26.
   PubMed Web of Science ®Google Scholar
• Bobes J, Garcia-Portilla MP, Bascaran MT, et al. Quality of life in schizophrenic patients. Dialogues Clin Neurosci. 2007;9:215–226.
   PubMedGoogle Scholar
• Pompili M, Amador XF, Girardi P, et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry. 2007;6:10.
   PubMedGoogle Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764–771.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med. 2005;353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79–104.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute- phase pivotal trials. J Clin Psychopharmacol. 2008;28(2Suppl 1):S12–9.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28(2Suppl 1):S4–11.
   PubMedGoogle Scholar
• Meltzer HY. the role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21:106–115.
   PubMed Web of Science ®Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.
   PubMed Web of Science ®Google Scholar
• Fanapt (iloperidone) [package insert]. Rockville (MD): Vanda Pharmaceuticals Inc. Companies; 2009.
   Google Scholar
• Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25:904–914.
   PubMed Web of Science ®Google Scholar
• Strupczewski JT, Bordeau KJ, Chang Y, et al. 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem. 1995;38:1119–1131.
   PubMed Web of Science ®Google Scholar
• Morisset S, Sahm UG, Traiffort E, et al. Atypical neuroleptics enhance histamine turnover in brain via 5-Hydrox-ytryptamine2A receptor blockade. J Pharmacol Exp Ther. 1999;288:590–596.
   PubMed Web of Science ®Google Scholar
• Nutt DJ. Putting the ‘A’ in atypical: does α2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J Psychopharmacol. 1994;8:193–195.
   PubMed Web of Science ®Google Scholar
• Pierelli F, Adipietro A, Soldati G, et al. Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand. 1998;97:295–299.
   PubMed Web of Science ®Google Scholar
• Arif SA, Michell MM. Iloperidone: A new drug for the treatment of schizophrenia. Am J Health Syst Pharm. 2011;68(4):301–308.
   PubMed Web of Science ®Google Scholar
• Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther. 2010;4:33–48.
   PubMed Web of Science ®Google Scholar
• Borison RL, Huff FJ, Griffiths L. Efficacy of 4 mg/day and 8 mg iloperidone administered to schizophrenic patients for 42 days. Psychopharmacol Bull. 1996;32:416.
   Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute phase pivotal trials. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S12–19.
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(7 suppl 1):S20–S28.
   PubMedGoogle Scholar
• Weiden PJ, Manning R, Wolfgang CD, et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS Drugs. 2016;30(8):735–747.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Citrome L, Alva G, et al. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophr Res. 2014;153(1–3):160–168.
   PubMed Web of Science ®Google Scholar
• Citrome L, Weiden PJ, Alva G, et al. Switching to iloperidone: an omnibus of clinically relevant observations from a 12-week, openlabel, randomized clinical trial in 500 persons with schizophrenia. Clin Schizophr Relat Psychoses. 2015;8(4):183–195.
   PubMedGoogle Scholar
• Cutler AJ, Kalali AH, Mattingly GW, et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013;18(1):43–54.
   PubMed Web of Science ®Google Scholar
• Kane JM, Lauriello J, Laska E, et al. Long-Term Efficacy and Safety of Iloperidone: results from 3 Clinical Trials for the Treatment of Schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl 1):S29–35.
   PubMed Web of Science ®Google Scholar
• Freeman SA. Iloperidone-induced retrograde ejaculation. Int Clin Psychopharm. 2013;28(3):156.
   PubMed Web of Science ®Google Scholar
• Ravani NN, Katke PH. Iloperidone-induced ejaculatory dysfunction: a case series. Indian J Psychiatry. 2016;58(1):87–89.
   PubMed Web of Science ®Google Scholar
• Achalia R, Andrade C. Ventricular premature contractions associated with iloperidone. Indian J Psychiatry. 2013;55(2):195–196.
   PubMed Web of Science ®Google Scholar
• Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTR2C – 759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res. 2010;175(3):271–273.
   PubMed Web of Science ®Google Scholar
• LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, Iloperidone; 2012. cited 2018 Apr 15; Available from: https://www-ncbi-nlm-nih-gov.ezp.slu.edu/books/NBK548669/
   Google Scholar
• Fanapt Prices, Coupons & Savings Tips. (n.d.). cited 2020 Feb 1. Available from: https://www.goodrx.com/fanapt
   Google Scholar
• Drugs and lactation database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US), Iloperidone; 2006. Updated 2018 Dec 3; Available from: https://www-ncbi-nlm-nih-gov.ezp.slu.edu/books/NBK501699/
   Google Scholar